Seaport Res Ptn Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS)

Seaport Res Ptn reaffirmed their buy rating on shares of Hims & Hers Health (NYSE:HIMS) in a report published on Friday morning, Zacks.com reports.

Several other equities analysts also recently weighed in on HIMS. Jefferies Financial Group reaffirmed a hold rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a buy rating and a $20.00 target price on the stock. SVB Leerink began coverage on Hims & Hers Health in a research report on Monday, February 26th. They issued a market perform rating and a $10.00 price objective on the stock. Truist Financial increased their target price on Hims & Hers Health from $10.00 to $13.00 and gave the stock a hold rating in a research report on Tuesday, February 27th. Finally, Citigroup lifted their target price on Hims & Hers Health from $12.00 to $16.00 and gave the company a buy rating in a research note on Tuesday, February 27th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $14.85.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $12.74 on Friday. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16. The business has a fifty day moving average price of $13.80 and a 200-day moving average price of $10.14. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -114.05 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. The business’s quarterly revenue was up 47.4% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health will post 0.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 97,208 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the sale, the chief executive officer now directly owns 51,653 shares in the company, valued at approximately $494,835.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 31,363 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $10.03, for a total value of $314,570.89. Following the sale, the chief financial officer now owns 156,721 shares in the company, valued at approximately $1,571,911.63. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 533,050 shares of company stock worth $7,191,666. Insiders own 31.63% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in shares of Hims & Hers Health by 17.9% during the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after purchasing an additional 2,525 shares during the period. Cornerstone Investment Partners LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at about $161,000. First National Trust Co bought a new position in Hims & Hers Health in the 1st quarter worth about $232,000. Summit Trail Advisors LLC increased its position in shares of Hims & Hers Health by 187.5% during the first quarter. Summit Trail Advisors LLC now owns 270,784 shares of the company’s stock worth $4,189,000 after acquiring an additional 176,612 shares during the period. Finally, Lake Street Private Wealth LLC bought a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $650,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.